Department of Urology, Odense University Hospital, Odense, Denmark.
Peritus Clinic, Lund, Sweden.
BMC Res Notes. 2022 May 21;15(1):185. doi: 10.1186/s13104-022-06076-2.
To introduce salvage prostatectomy in Denmark. Prior to this, no national curative treatment for recurrent prostate cancer following radiation therapy existed in Denmark. This pilot study represent our initial experiences and the feasibility of performing salvage robot-assisted radical prostatectomy for true local, high-risk recurrence after initial therapy with external beam radiation for high-risk prostate cancer.
Five patients underwent sRARP between April 2020 and July 2021. All patients were discharged within 48 h and no major complications were observed within 3 months. All patients had unmeasurable PSA (< 0.1 ng/ml) at follow-up 6 months after surgery. One patient with longer follow-up than 6 months experienced biochemical recurrence. At 3-months follow-up all patients reported considerable incontinence, at 6-month follow-up, pad usage decreased to 1 or 2 pads daily. Based on our initial results, the idea to introduce sRARP as a nationwide option remains and further patients will be included to establish the true role of sRARP in patients with recurrence after primary radiotherapy for PCa.
介绍丹麦的挽救性前列腺切除术。在此之前,丹麦对于放疗后复发性前列腺癌没有全国性的治愈性治疗方法。这项初步研究代表了我们的初步经验,以及对初始治疗为高风险前列腺癌的外照射后真正局部、高风险复发患者进行挽救性机器人辅助根治性前列腺切除术的可行性。
2020 年 4 月至 2021 年 7 月,5 例患者接受了 sRARP。所有患者均在 48 小时内出院,3 个月内无重大并发症。所有患者术后 6 个月随访时 PSA 均不可测(<0.1ng/ml)。1 例随访时间超过 6 个月的患者出现生化复发。3 个月随访时,所有患者均报告有明显尿失禁,6 个月随访时,尿垫使用量减少到每天 1 或 2 片。基于我们的初步结果,将 sRARP 作为一种全国性选择的想法仍然存在,将进一步纳入更多患者以确定 sRARP 在初发放疗后前列腺癌复发患者中的真正作用。